{
  "docId": "019de075-1362-766d-ac60-1333cab868aa",
  "docSlug": "7fe2865adefd4e627357f5c080658aba",
  "documentTitle": "Alkermes | Investor Presentation Deck | 56 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 56,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The table categorizes products into 'Proprietary' and 'Royalty' streams.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1362-766d-ac60-1333cab868aa/17",
  "deckHref": "/decks/019de075-1362-766d-ac60-1333cab868aa",
  "deckJsonHref": "/decks/019de075-1362-766d-ac60-1333cab868aa.json",
  "deckAnchorHref": "/decks/019de075-1362-766d-ac60-1333cab868aa#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "callout",
      "text": "One of the few mid-cap biotech companies to have internally developed multiple FDA-approved products",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "188a6127-5269-41d0-857e-c4fd4b362e67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "Under the terms of a settlement... [detailed footnotes]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2fa0180-791c-4263-a76b-7845a481fd71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.17
      },
      "kind": "table",
      "text": "Table showing Indication, Q1 23 LTM Rev, Approval Date, Remaining Patent Life, and Differentiation for Vivitrol, Aristada, Lybalvi, and Vumerity.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b514fdb-2040-430a-b807-7514bb5b08b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Developed Attractive Commercial Neuroscience Portfolio",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8eeb886e-de23-4fc7-961c-9db53476ad77",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "456ee3e4-026a-442c-9438-289bfd81ee8a",
      "arcName": "The Transformation Tale",
      "arcSlug": "transformation-tale",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 13-20 provide evidence of Alkermes' successful execution and growth.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 17,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "8c753e0f-bc7c-4296-afd3-cccb0d4a6d82",
      "evidence": "Slides 17-20 provide a MECE breakdown of Alkermes' growth and profitability.",
      "position": 1,
      "objective": "Break down Alkermes' growth and profitability drivers",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.6,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}